Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALL09 - Phase II Study of Blinatumomab as Induction Therapy in Adolescent and Young Adult Acute Lymphoblastic Leukaemia

Next Previous
Trial Profile

ALL09 - Phase II Study of Blinatumomab as Induction Therapy in Adolescent and Young Adult Acute Lymphoblastic Leukaemia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms The SUBLIME Study

Most Recent Events

  • 10 Dec 2024 Results consisting patient-reported HRQoL in participants from ALL09 presented at the 66th American Society of Hematology Annual Meeting and Exposition.
  • 12 Dec 2023 Results from this and other study assessing impact of blin on outcomes in genomic cohorts, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 13 Dec 2022 Primary endpoint (To assess the rate of minimal residual disease (MRD) negativity, where MRD negativity is defined as no presence of leukaemic blasts in blood or bone marrow sample as determined by EuroMRD accredited q-pcr analysis) has been met according to results presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top